- Home
- STAA vs GERN Comparison
STAA vs GERN Comparison
Compare STAA & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STAA
- GERN
- Stock Information
- Founded
- STAA 1982
- GERN 1990
- Country
- STAA United States
- GERN United States
- Employees
- STAA N/A
- GERN N/A
- Industry
- STAA Ophthalmic Goods
- GERN Biotechnology: Pharmaceutical Preparations
- Sector
- STAA Health Care
- GERN Health Care
- Exchange
- STAA Nasdaq
- GERN Nasdaq
- Market Cap
- STAA 850.9M
- GERN 974.5M
- IPO Year
- STAA N/A
- GERN 1996
- Fundamental
- Price
- STAA $19.20
- GERN $1.26
- Analyst Decision
- STAA Hold
- GERN Buy
- Analyst Count
- STAA 7
- GERN 8
- Target Price
- STAA $18.20
- GERN $3.71
- AVG Volume (30 Days)
- STAA 690.3K
- GERN 9.0M
- Earning Date
- STAA 08-06-2025
- GERN 08-07-2025
- Dividend Yield
- STAA N/A
- GERN N/A
- EPS Growth
- STAA N/A
- GERN N/A
- EPS
- STAA N/A
- GERN N/A
- Revenue
- STAA $279,134,000.00
- GERN $116,293,000.00
- Revenue This Year
- STAA N/A
- GERN $161.44
- Revenue Next Year
- STAA $27.83
- GERN $53.06
- P/E Ratio
- STAA N/A
- GERN N/A
- Revenue Growth
- STAA N/A
- GERN 22264.04
- 52 Week Low
- STAA $13.50
- GERN $1.17
- 52 Week High
- STAA $42.17
- GERN $4.89
- Technical
- Relative Strength Index (RSI)
- STAA 64.07
- GERN 41.41
- Support Level
- STAA $16.80
- GERN $1.20
- Resistance Level
- STAA $19.37
- GERN $1.37
- Average True Range (ATR)
- STAA 0.62
- GERN 0.08
- MACD
- STAA 0.26
- GERN -0.00
- Stochastic Oscillator
- STAA 93.63
- GERN 21.43
About STAA STAAR Surgical Company
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of its sales are generated from the ophthalmic surgical product segment.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.